NLRP3-IN-33
NLRP3-IN-33 (Compound 12o) is a blood-brain barrier permeable inhibitor of AChE and BChE, with IC50 values of 1.02 μM and 7.03 μM against hAChE and hBChE respectively. NLRP3-IN-33 possesses antioxidant, anti-inflammatory, and metal chelating activities, making it a potential candidate for research in Alzheimer's disease (AD).
For research use only. We do not sell to patients.
- Formula: C21H19N3O5
- Molecular Weight:393.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
NLRP3-IN-33 (12o) (1-30 μM; 24 h) exhibits no significant cytotoxicity in PC-12 cells[1]. NLRP3-IN-33 possesses antioxidant activity and can inhibit the generation of free radicals, with an IC50 value of 6.19 μM. 12o (1-20 μM; 24 h) effectively alleviates H2O2 (600 μM; 24 h)-induced oxidative stress and exhibits neuroprotective effects in PC-1 cells[1]. NLRP3-IN-33 (1-20 μM; 24 h) also inhibits the activation of the NLRP3 inflammasome in PC-1 cells and mitigates the damage caused by mitochondrial-induced reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) triggered by LPS (1 μg/mL) and ATP (5 mM) in HMC-3 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HMC-3
-
Concentration:12.5 μM, 25 μM
-
Incubation Time:24 h
-
Result:Inhibited the NLRP3 inflammasome activation and caspase-1 release.
Significantly decreased the expression of NF-κB and NLRP3 proteins.
NLRP3-IN-33 (5 mg/kg; i.p.; once daily for 22 consecutive days) is capable of improving memory and cognitive impairments in AD mouse models induced by Scopolamine (HY-N0296) (1.4 mg/kg; i.p.; once daily for 5 consecutive days)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Alzheimer's disease (AD) fractional model[1]
-
Dosage:1 mg/kg, 5 mg/kg
-
Administration:Intraperitoneal injection (i.p.); Once daily for 22 days. Received scopolamine (HY-N0296) (1.4 mg/kg; i.p.; once daily for 5 days) on the last 5 days of the experiment (day 18 to day 22).
-
Result:Significantly shortened escape latency time as compared to the scopolamine-treated group.
Chemical Information
-
Molecular Weight 393.39
-
Formula C21H19N3O5
-
SMILES
O=C(NCC(NC1=C2C=CC=NC2=C(O)C=C1)=O)/C=C/C3=CC=C(O)C(OC)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NLRP3-IN-33 Related Classifications
HY-162402 Related Classifications
Powered by Bioz